John P Logue

Intermittent Androgen Suppression for Rising PSA Level After Radiotherapy

Joseph L. Chin, Celestia S. Higano, Fred Saad, 2013 .

Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: Results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases.

Sten Nilsson, Arne Solberg, Joe M O'Sullivan, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intermittent androgen suppression for rising PSA level after radiotherapy.

Fred Saad, Emma Hall, Graeme Duncan, 2012, The New England journal of medicine.

Scoring of treatment-related late effects in prostate cancer.

R. Cowan, J. Logue, J. Livsey, 2002, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Prediction of radiotherapy outcome using dynamic contrast enhanced MRI of carcinoma of the cervix.

David L Buckley, J. R. Sykes, Catharine M L West, 2002, International journal of radiation oncology, biology, physics.

Trans-perineal implantation of radio-opaque treatment verification markers into the prostate: an assessment of procedure related morbidity, patient acceptability and accuracy.

V. Khoo, J. Logue, A. Henry, 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.